These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23172086)

  • 1. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
    Dabner M; Harvey NT; Soma A; Wood BA
    Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
    [No Abstract]   [Full Text] [Related]  

  • 2. Second primary melanomas on treatment with vemurafenib.
    Dalle S; Poulalhon N; Debarbieux S; Thomas L
    Br J Dermatol; 2013 Apr; 168(4):887-8. PubMed ID: 23066856
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
    Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
    Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
    [No Abstract]   [Full Text] [Related]  

  • 6. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second primary melanomas on treatment with vemurafenib: reply from the authors.
    Fearfield L; Newton-Bishop JA; Sinha R; Edmonds K; Gore ME; Larkin J
    Br J Dermatol; 2013 Apr; 168(4):888-9. PubMed ID: 23066884
    [No Abstract]   [Full Text] [Related]  

  • 8. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis.
    Chaminade A; Conte H; Jouary T; Fauconneau A; Darrigade AS; Beylot-Barry M; Pham-Ledard A
    J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):392-393. PubMed ID: 24533578
    [No Abstract]   [Full Text] [Related]  

  • 10. Vemurafenib-induced DRESS.
    Wenk KS; Pichard DC; Nasabzadeh T; Jang S; Venna SS
    JAMA Dermatol; 2013 Oct; 149(10):1242-3. PubMed ID: 23986488
    [No Abstract]   [Full Text] [Related]  

  • 11. Vemurafenib-induced granuloma annulare.
    Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
    [No Abstract]   [Full Text] [Related]  

  • 12. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
    Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
    Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
    Gabeff R; Dutartre H; Khammari A; Boisrobert A; Nguyen JM; Quereux G; Brocard A; Saint-Jean M; Peuvrel L; Dreno B
    Eur J Dermatol; 2015; 25(5):452-6. PubMed ID: 26242321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vemurafenib-induced toxic epidermal necrolysis].
    Wantz M; Spanoudi-Kitrimi I; Lasek A; Lebas D; Quinchon JF; Modiano P
    Ann Dermatol Venereol; 2014 Mar; 141(3):215-8. PubMed ID: 24635957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAFi-associated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature.
    Ferreira J; Toda-Brito H; Moura MC; Sachse MF; Costa-Rosa J
    J Cutan Pathol; 2017 Mar; 44(3):307-309. PubMed ID: 27976808
    [No Abstract]   [Full Text] [Related]  

  • 16. Lupus erythematosus-like skin eruption after vemurafenib therapy.
    Reinholz M; Berking C; Hermans C; Ruzicka T; Braun-Falco M
    J Am Acad Dermatol; 2014 Oct; 71(4):e159-60. PubMed ID: 25219748
    [No Abstract]   [Full Text] [Related]  

  • 17. Vemurafenib and cutaneous adverse events--report of five cases.
    Silva Gde B; Mendes AP; de Macedo MP; Pinto CA; Gibbons IL; Duprat Neto JP
    An Bras Dermatol; 2015; 90(3 Suppl 1):242-6. PubMed ID: 26312729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perforated intestinal metastasis while taking the BRAF inhibitor, vemurafanib.
    Welsh F; Chang WK; Purchas S
    ANZ J Surg; 2014 Nov; 84(11):891. PubMed ID: 25348915
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of metastatic melanoma with BRAF inhibitors].
    Hafner C
    Hautarzt; 2011 Sep; 62(9):696-8. PubMed ID: 21863388
    [No Abstract]   [Full Text] [Related]  

  • 20. RASopathic alopecia: hair changes associated with vemurafenib therapy.
    Piraccini BM; Patrizi A; Fanti PA; Starace M; Bruni F; Melotti B; Misciali C; Dika E
    J Am Acad Dermatol; 2015 Apr; 72(4):738-41. PubMed ID: 25773419
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.